Klivira
Request demo

Optimizing Kesimpta Prior Authorization for Cardiology Practices

While Kesimpta is not a primary cardiology medication, efficiently managing Kesimpta prior authorization for cardiology patients, alongside complex cardiac procedures and specialty drugs, is crucial for revenue cycle integrity.

Cardiology practices face a dual challenge: the high volume of prior authorizations for advanced imaging, interventional procedures, electrophysiology, and specialty cardiovascular drugs, coupled with the administrative burden of managing PAs for any high-volume medication a patient may require. Klivira provides a unified platform to automate these diverse prior authorization workflows, ensuring compliance and efficiency.

Navigating High-Volume Drug Prior Authorizations Like Kesimpta

Kesimpta, while primarily indicated for conditions outside of cardiology, represents a class of high-volume specialty drugs that frequently trigger prior authorization across commercial, Medicare Advantage, and Medicaid managed care plans. For cardiology practices whose patients may be prescribed such medications for comorbid conditions, efficient PA processing is essential to prevent treatment delays and revenue cycle bottlenecks.

The Complex Landscape of Cardiology Prior Authorizations

Prior authorization in cardiology is extensive, covering advanced cardiac imaging, interventional procedures, electrophysiology, and specialty cardiovascular drugs. This complexity often involves multiple payer channels, specialty benefit-management vendors, and stringent clinical documentation requirements based on guidelines from bodies like ACC/AHA and ACR Appropriateness Criteria.

Critical Documentation for Cardiology Prior Authorization Approval

  • Ejection fraction and NYHA functional class for ICD/CRT eligibility
  • Clinical question, pre-test probability, and prior imaging history for advanced cardiac imaging
  • Symptoms, functional limitation, and prior stress testing results for cardiac catheterization
  • LDL levels on maximum tolerated statin therapy for PCSK9 inhibitors
  • Optimal medical therapy duration documentation for primary prevention device implants

Common Prior Authorization Denial Reasons in Cardiology

Cardiology PAs frequently encounter denials due to inappropriate use criteria for advanced imaging, step therapy requirements (e.g., conservative imaging before stress testing), and documentation gaps regarding ejection fraction or optimal medical therapy duration. Klivira's platform helps identify and mitigate these common pitfalls before submission.

Streamlining Prior Authorization Workflows with Klivira

Klivira's platform automates prior authorization across the diverse needs of a cardiology practice, from high-volume drug PAs like Kesimpta to complex cardiac procedures. Our system intelligently routes requests to appropriate channels, including specialty benefit-management vendors such as Carelon MBM or eviCore / successor vendors, reducing manual effort and accelerating approvals.

Klivira's Capabilities for Cardiology Prior Authorization

  • Automated identification and routing to specialty benefit-management vendors for advanced imaging and devices.
  • Policy logic incorporating ACR Appropriateness Criteria for advanced cardiac imaging.
  • Dedicated workflow support for longer lead-time device PAs (ICD/CRT/structural-heart).
  • Intelligent routing and step-therapy logic for specialty cardiovascular drugs.
  • Seamless EMR integration via SMART on FHIR for efficient data exchange.

Frequently asked questions

How does Klivira handle prior authorization for high-volume drugs like Kesimpta, which are not primary cardiology medications?

Klivira's platform is designed to manage prior authorizations for any high-volume specialty drug, including Kesimpta, regardless of the prescribing specialty. We automate the submission process, track payer requirements, and integrate with EMRs to streamline documentation, ensuring efficient processing even for medications outside a practice's primary focus.

What are the primary prior authorization challenges for advanced cardiac imaging?

Advanced cardiac imaging, such as cardiac MRI or nuclear stress imaging, faces challenges like stringent payer-specific appropriateness criteria (often via specialty benefit managers), requirements for prior imaging history, and high denial rates for inappropriate use. Klivira automates routing to these vendors and applies policy logic to align with criteria like ACR Appropriateness.

Does Klivira integrate with specialty benefit-management vendors commonly used in cardiology?

Yes, Klivira automatically identifies and routes prior authorization requests to major specialty benefit-management vendors prevalent in cardiology, including Carelon MBM and eviCore / successor vendors. This capability reduces manual portal navigation and ensures requests reach the correct entity quickly.

What specific documentation is critical for ICD or CRT prior authorizations?

For ICD/CRT prior authorizations, critical documentation typically includes ejection fraction (often ≤35% for primary prevention), NYHA functional class, evidence of optimal medical therapy duration, and QRS morphology/duration for CRT eligibility. Klivira helps ensure these details are captured and submitted accurately.

How does Klivira assist in reducing prior authorization denials for cardiology procedures?

Klivira reduces denials by ensuring submissions align with payer-specific guidelines and clinical appropriateness criteria. Our system helps identify common denial reasons, such as missing step-therapy documentation or insufficient clinical rationale, prompting users to provide necessary information before submission to improve first-pass approval rates.

Related coverage

Other kesimpta prior authorization by payer

Other kesimpta prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo